featured
Circulating Tumor DNA Predicts Clinical Outcomes in NSCLC Patients
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Detection and Dynamic Changes of EGFR Mutations From Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated With First-Line Intercalated Erlotinib and Chemotherapy
Clin. Cancer Res 2015 Mar 31;[EPub Ahead of Print], TS Mok, YL Wu, J Soo Lee, CJ Yu, V Sriuranpong, J Sandoval-Tan, G Ladrera, S Thongprasert, V Srimuninnimit, M Liao, Y Zhu, C Zhou, F Fuerte, B Margono, W Wen, J Tsai, M Truman, B Klughammer, DS Shames, L WuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.